HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Primary neuroblastoma uptake of 99mtechnetium methylene diphosphonate.

Abstract
Forty patients, ages three days to 12 years, with neuroblastomas had bone scans with 99mtechnetium methylene diphosphonate (99mTc-MDP) as part of their pretreatment examination. Twenty-four (60%) had primary tumor uptake and 16 (40%) did not. No difference was seen between the two groups in the incidence of tumor calcification or necrosis. No relationship between the level of urinary vanillylmandelic acid (VMA) and the presence of primary tumor uptake of 99mTc-MDP was found. The possible causes for the localization of 99mTc-MDP are discussed.
AuthorsF W Smith, D L Gilday, J M Ash, R H Reid
JournalRadiology (Radiology) Vol. 137 Issue 2 Pg. 501-4 (Nov 1980) ISSN: 0033-8419 [Print] United States
PMID6449027 (Publication Type: Journal Article)
Chemical References
  • Diphosphonates
  • Vanilmandelic Acid
  • Technetium
  • Technetium Tc 99m Medronate
Topics
  • Adrenal Gland Neoplasms (diagnostic imaging, metabolism)
  • Bone and Bones (diagnostic imaging, metabolism)
  • Calcinosis (metabolism)
  • Child
  • Child, Preschool
  • Diphosphonates (metabolism)
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Mediastinal Neoplasms (diagnostic imaging, metabolism)
  • Necrosis
  • Neuroblastoma (diagnostic imaging, metabolism, pathology)
  • Radionuclide Imaging
  • Technetium (metabolism)
  • Technetium Tc 99m Medronate
  • Vanilmandelic Acid (urine)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: